Navigation Links
Data from Clinical Studies of bioTheranostics' CancerTYPE ID® and Breast Cancer Index(SM) Molecular Diagnostic Tests Presented at ASCO 2011 Annual Meeting
Date:6/7/2011

SAN DIEGO, June 7, 2011 /PRNewswire/ -- bioTheranostics, Inc., a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company's CancerTYPE ID®, and Breast Cancer Index(SM). Data from the studies were presented this week at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago.

On June 6, scientists from bioTheranostics and the Institut Gustave-Roussy (France) presented results from a study evaluating the utility of the Breast Cancer Index(SM) (BCI) for predicting pathologic complete response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy.  In the study, patients with a high BCI score had a more favorable response to standard chemotherapies such as anthracycline and taxane (P=0.02).

"Patients determined as high-risk by BCI had a 10-fold greater probability of pCR with the chemotherapy regimen when compared to the low risk patients," said Mark Erlander, Ph.D., chief scientific officer, bioTheranostics. "These results suggest that BCI is predictive of chemotherapy response."

bioTheranostics also presented diagnostic utility data for CancerTYPE ID® from a study of 754 metastatic cancer cases.  The results showed that pre-CancerTYPE ID® pathological workup involved a mean of seven immunohistochemistry (IHC) stains to identify the cancer site of origin.  Increasing the number of IHC stains beyond seven lengthened the diagnostic process without improving the accuracy of the final result.

"Quickly and accurately diagnosing the site of origin is critical in the care of metastatic cancer patients," said Richard Ding, chief executive officer, bioTheranostics.  "This study illustrated that the current diagnostic process is not standardized and often time- consuming."  In the study, CancerTYPE ID required only five days of lab processing to predict a single primary site in more than 90 percent of the cases, and provided a more objective and informative diagnosis to physicians.

Finally, in collaboration with a group of international clinicians, bioTheranostics presented data from a study evaluating the utility of a novel P95 assay. The study assessed the assay's ability to identify the truncated form of the Her2 gene in Her2-positive breast cancer patients as a means to predict trastuzumab response.

About bioTheranostics

Advancing Molecular Diagnostics in Oncology

bioTheranostics discovers, develops and commercializes molecular diagnostic tests for cancer patients. Leveraging its unique expertise in expression profiling and algorithm development, bioTheranostics provides innovative tests to the oncology community. The company operates a CLIA-certified, CAP-accredited diagnostic service laboratory in San Diego, CA to perform its proprietary molecular diagnostic tests: Breast Cancer Index(SM), which is a prognostic test that provides quantitative risk assessment of distant recurrence in patients diagnosed with estrogen receptor positive and lymph node negative breast cancer; and the CancerTYPE ID® test, which uses the differential expression of 92 genes to aid in the determination of tumor site of origin. For more information call 1-858-587-5870 or visit www.bioTheranostics.com.

About bioMerieux

Advancing Diagnostics to Improve Public Health

A world leader in the field of in vitro diagnostics for over 45 years, bioMerieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2010, revenues reached €1.357 billion with 87% of sales outside of France.

bioMerieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in
agri-food, pharmaceutical and cosmetic products.

bioMerieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479).

Other information can be found at www.biomerieux.com

bioTheranostics Contacts

Tim Schofield
Tel: + 1 858 587 5890
tim.schofield@biotheranostics.com

Michele Parisi
Tel: + 1 925 864 5028
mparisi@biocommnetwork.com

bioMerieux Contact

Koren Wolman-Tardy
Tel: + 011 33 6 13 94 51 14
media@eu.biomerieux.com


'/>"/>
SOURCE bioTheranostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tocagens First-in-Human Clinical Trial of Toca 511 Enrolling Patients with High Grade Glioma
2. Precision Therapeutics Presents Clinical Study Emphasizing the Role of ChemoFx® in Directing Chemotherapy in Gynecological Cancers
3. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
4. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
5. Late-Breaking ASCO Data Demonstrate Circulating Tumor Cells as Potential Biomarker for Metastatic Prostate Cancer Clinical Trials
6. Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
7. Spherix Drug Candidate SPX-106 Shows Statistically Significant Reductions in Serum Triglycerides in Preclinical Testing
8. IDEV Technologies Announces Completion of SUPERB Clinical Trial Enrollment
9. Investment in Oncology Drug Development Remains Strong as 133 Companies Initiate Late-Stage Clinical Trials Representing a 21% Increase
10. PLC Ramps Up for U.S. Clinical Trial of RenalGuard®
11. Bionovo to Present the Clinical Promise of Menerba (MF101) for Postmenopausal Vasomotor Symptoms at World Congress on Menopause
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... March 29, 2017  Maxor National Pharmacy Services, LLC ... it has named Leah Bailey as General ... of the company. With more than 13 ... 8 years focused on health care, Bailey joins the ... at Prime, Bailey advised the PBM, Specialty, and Mail ...
(Date:3/29/2017)... WASHINGTON , March 29, 2017  The Pharmaceutical ... regarding a new PhRMA report on patient out-of-pocket spending: ... for Medicare and Medicaid Services (CMS), the average amount ... be 13% of drug spending in 2016, down from ... is a pricing problem, not a coverage problem. Health ...
(Date:3/29/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The ablation device global market is expected to grow ... Ablation is the minimally invasive therapeutic tissue excision ... diseased tissue removal, to the removal of abnormally conducting cardiac tissue ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... ... Curio Wellness , a premium medical cannabis brand and trusted healthcare ... team with prominent executives from both inside and outside the cannabis industry. , ... Dumbauld , who has more than twenty years of business leadership and investment experience ...
(Date:3/29/2017)... ... March 29, 2017 , ... HealthCareMandA.com will host an important webinar — ... 1:00 PM ET. A recording of the webinar will also be made available following ... health and hospice companies are still popular targets for healthcare investors. This highly fragmented ...
(Date:3/29/2017)... ... 2017 , ... Immunotherapy has emerged as one of the most promising options ... be the next revolution in our fight against this complex disease. One of the ... checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a few single analyte ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... Hills of Pittsburgh now have easier access to the robotic-assisted total-hip and ... Health Network (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson Hospital recently ...
(Date:3/29/2017)... ... , ... The Wharton School of the University of Pennsylvania is pleased to ... $10 million gift to establish the Ken Moelis and Julie Taffet Moelis Advance ... Wharton MBA for highly-qualified Penn undergraduates whose academic and career interests expand traditional notions ...
Breaking Medicine News(10 mins):